TMEM229B Inhibitors
TMEM229B inhibitors encompass a diverse array of chemical compounds that target specific signaling pathways and cellular processes to achieve their inhibitory effect on the protein's activity. Inhibitors that thwart the PI3K/Akt and MAPK/ERK pathways are especially significant, as they impede critical phosphorylation events, thus potentially restricting the downstream effects that could be essential for TMEM229B function. These compounds effectively disrupt the signaling cascade right at the kinases, ensuring that subsequent cellular responses dependent on these pathways are attenuated. Additionally, compounds that inhibit p38 MAPK are notable for their ability to suppress the inflammatory response, which could be crucial if TMEM229B is involved in such processes. Similarly, Rho-associated kinase (ROCK) inhibitors alter the cytoskeletal dynamics and cell adhesion, pathways which could be intrinsic to the functional role of TMEM229B.
Other inhibitors act by modifying the intracellular levels of key ions and molecules, thus affecting TMEM229B indirectly. Calcium signaling, for instance, is targeted by various inhibitors that either sequester calcium ions or block channels and transporters, thereby altering the flow of calcium into and out of cells. Since calcium is a ubiquitous second messenger involved in numerous cellular functions, its dysregulation could have downstream effects on the stability and activity of TMEM229B, particularly if it is sensitive to calcium-mediated signaling. Additionally, inhibitors that interfere with the homeostasis of reactive oxygen species (ROS) can influence TMEM229B activity. By reducing or increasing intracellular ROS levels, these inhibitors can affect signaling pathways and transcriptional events that might control TMEM229B expression or stability.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3Ks), which interrupts the PI3K/Akt signaling pathway. Inhibition of this pathway will decrease phosphorylation and activation of various downstream targets, potentially diminishing TMEM229B activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK, leading to the suppression of MAPK signaling. By impeding this pathway, the inflammatory response is attenuated, which may result in a reduction of TMEM229B activity if it is associated with inflammatory processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which blocks the activation of MAPK/ERK kinase. By preventing the phosphorylation of ERK, downstream signaling is inhibited, potentially reducing the activity of TMEM229B if it is ERK pathway-dependent. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist that interferes with calcium-calmodulin-dependent signaling processes. This compound could reduce TMEM229B activity by inhibiting calmodulin's regulatory functions on various kinases and phosphatases. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
A broad-spectrum protein kinase C inhibitor, which impedes the PKC-mediated signal transduction pathway. This inhibition may affect TMEM229B activity by altering PKC-dependent cellular responses. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
An inhibitor of myosin light chain kinase (MLCK), potentially affecting the cytoskeleton dynamics and cellular motility. TMEM229B activity could be indirectly diminished if it relies on MLCK-mediated processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
A cell-permeable calcium chelator that reduces intracellular free calcium levels, likely influencing calcium-dependent signaling pathways. This chelation could indirectly decrease TMEM229B activity if it is modulated by calcium signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may attenuate the JNK signaling pathway. If TMEM229B activity is associated with JNK pathway, inhibition could lead to decreased TMEM229B functional activity. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $500.00 | 14 | |
An inhibitor of inositol trisphosphate (IP3) receptor, suppressing the release of calcium from the endoplasmic reticulum. Reduced calcium signaling could indirectly inhibit TMEM229B if its activity is calcium-dependent. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of Rho-associated protein kinase (ROCK), which may modulate actin cytoskeleton arrangement and cell adhesion. TMEM229B activity could be impacted if it is associated with pathways involving ROCK. | ||||||